Drug Approval | March 21, 2022
USFDA approves Perrigo’s Nasonex
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Subscribe To Our Newsletter & Stay Updated
